LSTA — Lisata Therapeutics Share News
0.000.00%
Last trade - 00:00- $10.91m
- $0.22m
- $0.17m
Brief: Lisata Therapeutics Inc Reports Quarterly Loss Per Share Of $0.76
Lisata Therapeutics Inc expected to post a loss of $1.01 a share - Earnings Preview
Lisata Therapeutics Inc expected to post a loss of $1.01 a share - Earnings Preview
Lisata Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Lisata Therapeutics Reports Third Quarter 2022 Financial Results And Provides Business Update
Lisata Therapeutics Inc expected to post a loss of 90 cents a share - Earnings Preview
Lisata Therapeutics Inc expected to post a loss of 90 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Johnson & Johnson, Altimmune, Twilio
Caladrius soars as stockholders approve merger with Cend Therapeutics
Brief: Caladrius Biosciences Announces Approval Of Merger And Name Change To Lisata Therapeutics
Brief: Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement With Roche
Brief: Caladrius Biosciences Reports Second Quarter 2022 Financial Results And Provides Business Update
Brief: Caladrius Biosciences And Cend Therapeutics Announce Publication Of Pancreatic Cancer Trial Data In The Lancet Gastroenterology And Hepatology
Brief: Caladrius Biosciences Says Cend Therapeutics Treated First Patient In Phase 2B Trial Of Cend-1
Brief: Caladrius Biosciences Provides Update On Phase 2B Freedom Trial Of Xowna® In Coronary Microvascular Dysfunction
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:17 PM
Brief: Caladrius Biosciences Announces Idmc Recommendation To Advance Clbs201 Trial For Treatment Of Diabetic Kidney Disease
Brief: Caladrius Biosciences Reports First Quarter 2022 Financial Results
Caladrius Biosciences Inc expected to post a loss of 10 cents a share - Earnings Preview